SurModics tumbles into red ink
SurModics Inc. (NSDQ:SRDX) reported a loss of $21.7 million, or $1.25 per diluted share, on revenue of $15.5 million during the three months ended Sept. 30. That compares with profits of $2.7 million, or 16 cents per diluted share, on revenue of $19.2 million during the same period last year. The company’s 2010 fiscal year revenues were slightly more than half of the company’s 2009 revenues.
Read more

Bioject losses double as sales stagnate
Bioject Medical Technologies Inc. (OTC:BJCT) recorded a loss of approximately $357,000, or 2 cents per diluted share, on revenue of $1.5 million during the three months ended Sept. 30. That compares with a loss of approximately $187,000, or 1 cent per diluted share, on revenue of $1.5 million during the same period last year.
Read more

Losses outstrip revenue at Neoprobe
Neoprobe Corp. (OTC:NEOP) posted a loss of $2.4 million, or 3 cents per diluted share, on sales of $2.3 million during the three months ended Sept. 30. That compares with a loss of $25.1 million, or 34 cents per diluted share, on sales of $2.6 million during the same period last year.
Read more